Merrimack Pharmaceuticals, Inc. (MACK)
(Delayed Data from NSDQ)
$5.90 USD
+0.05 (0.85%)
Updated May 3, 2019 03:59 PM ET
After-Market: $5.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
MACK 5.90 +0.05(0.85%)
Will MACK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MACK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MACK
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
MACK: What are Zacks experts saying now?
Zacks Private Portfolio Services